Reviewing Cannabis Science (CBIS) and Signal Genetics (MGEN)
Cannabis Science (OTCMKTS: CBIS) and Signal Genetics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
This is a breakdown of current recommendations and price targets for Cannabis Science and Signal Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Cannabis Science has a beta of -4.04, suggesting that its share price is 504% less volatile than the S&P 500. Comparatively, Signal Genetics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cannabis Science and Signal Genetics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Signal Genetics||$3.34 million||53.50||-$12.67 million||$0.15||53.40|
Cannabis Science has higher earnings, but lower revenue than Signal Genetics.
This table compares Cannabis Science and Signal Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
22.6% of Signal Genetics shares are held by institutional investors. 44.4% of Signal Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Signal Genetics beats Cannabis Science on 8 of the 9 factors compared between the two stocks.
About Cannabis Science
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
About Signal Genetics
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings for Cannabis Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc. and related companies with MarketBeat.com's FREE daily email newsletter.